Bio-Techne (TECH) Azione Prezzo
Bio-Techne Prezzo
Il fatturato è cresciuto a un tasso composto del 9,3% annuo negli ultimi 19 anni, raggiungendo 1,22 miliardi USD. L'utile per azione è cresciuto del 4,1% all'anno negli ultimi 19 anni. Il margine netto di Bio-Techne si attesta al 15,0%, in calo rispetto al 24,6% di alcuni anni fa. Bio-Techne offre attualmente un rendimento da dividendo di circa il 0,44%. Il payout ratio è pari a circa il 40% degli utili. Il dividendo è cresciuto del 9,5% all'anno negli ultimi 18 anni. Gli analisti fissano un target di prezzo mediano di 73,00 USD, ovvero il 0,8% sopra il prezzo attuale. Su 22 analisti, 7 valutano il titolo come acquisto — nel complesso un consenso Mantenere.
Bio-Techne Prezzo delle azioni
Bio-Techne Azione e analisi azionaria
Domande frequenti sull'azione Bio-Techne
Bio-Techne Corp's business model revolves around providing innovative life science tools and solutions to researchers worldwide. The company focuses on developing and manufacturing high-quality reagents, assays, and instruments used in biomedical research, clinical diagnostics, and pharmaceutical development. With a diverse portfolio, Bio-Techne offers products for gene expression analysis, protein analysis, cell imaging, and stem cell research. Their advanced technologies and expertise enable scientists to accelerate discoveries and enhance their understanding of diseases, ultimately aiding in the development of new therapies. Bio-Techne Corp strives to be at the forefront of scientific advancements by continually investing in research and development initiatives.
Bio-Techne Corp primarily operates in the biotechnology and life sciences industries. Its extensive product portfolio includes cutting-edge solutions for research and diagnostics, spanning the fields of pharmaceuticals, clinical applications, bioprocessing, and academia. With a focus on developing innovative technologies, Bio-Techne Corp delivers products and services that support advancements in areas such as cancer research, stem cell research, immunology, neuroscience, and genetic analysis. As a leading player in these sectors, Bio-Techne Corp continues to make significant contributions to the scientific community and drive progress in the biotechnology field.
Some of the main competitors of Bio-Techne Corp in the market include Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies.
Bio-Techne Corp, formerly known as Techne Corporation, is a leading global life sciences company. Established in 1976, Bio-Techne has a rich history of innovation and scientific discovery. The company develops and manufactures a wide range of cutting-edge products and solutions for the biotechnology and clinical research industries. With a strong focus on research and development, Bio-Techne has consistently brought forth groundbreaking technologies and advanced tools, revolutionizing the understanding and treatment of diseases. Today, Bio-Techne Corp remains at the forefront of the life sciences industry, delivering high-quality products and driving advancements in scientific research worldwide.
Bio-Techne Corp has achieved several significant milestones. The company has successfully expanded its product portfolio, offering a wide range of innovative solutions in life sciences research and diagnostics. Bio-Techne Corp has also witnessed strong financial performance, consistently delivering impressive revenue growth over the years. Moreover, the company has made strategic acquisitions to enhance its capabilities and market presence. With a focus on advanced technologies and a commitment to innovation, Bio-Techne Corp continues to contribute to scientific advancements and improve healthcare outcomes globally.
Bio-Techne Corp is primarily present in various countries and regions worldwide. The company has a widespread global presence, with significant operations and a strong market presence in North America, Europe, and Asia-Pacific. This enables Bio-Techne Corp to serve a diverse customer base and tap into multiple international markets. Along with its headquarters in the United States, Bio-Techne Corp has strategic offices, production facilities, and distribution networks across key countries and regions globally. This expansive global footprint allows the company to effectively deliver its innovative biotechnology solutions and services to customers around the world.
Bio-Techne Corp is a leading global provider of life science products and solutions. The company values innovation, scientific excellence, and customer-centricity. Bio-Techne Corp's corporate philosophy revolves around advancing scientific discoveries and improving human health. With a strong commitment to research and development, Bio-Techne Corp focuses on providing cutting-edge tools and technologies to support the life science community. By fostering collaboration and investing in breakthrough technologies, the company aims to accelerate scientific progress and enable researchers to make significant contributions in the fields of genomics, proteomics, and cell biology. Overall, Bio-Techne Corp is dedicated to driving innovation and making a positive impact in the life science industry.
Gli analisti fissano attualmente un prezzo obiettivo medio di 65,78 USD per l’azione Bio-Techne (mediana: 73,00 USD), pari a -9,1 % rispetto all’ultimo prezzo. Il consenso si basa su 22 giudizi di analisti.
22 analisti valutano attualmente l’azione Bio-Techne: 7 raccomandano l’acquisto, 15 la tenuta e 0 la vendita.
Convertita al tasso di cambio attuale, l’azione Bio-Techne quota 64,36 EUR (72,40 USD).
L’azione Bio-Techne (TECH) è quotata su 4 borse, tra cui: NASDAQ (TECH), Frankfurt (TE1.F), München (TE1.MU), Düsseldorf (TE1.DU).
Bio-Techne Corp is a leading provider of innovative products for the biotechnology and clinical diagnostics industry. The company offers a wide range of products and services for protein research, cell analysis, microscopy, genomics, and clinical diagnostics. Protein research: Bio-Techne offers proteins, antibodies, reagents, and instruments for signal pathway research, protein expression, and function. Well-known brands in this field include R&D Systems, Novus Biologicals, Tocris, and ProteinSimple. Cell analysis: For cell analysis, Bio-Techne provides a wide range of products including cell analysis devices, reagents, and instruments for flow cytometry, cell culture, and microscopy. BioLegend is the leading brand for cell analysis products from Bio-Techne. Microscopy: Bio-Techne also offers a wide range of microscopy products for cell and tissue analysis. This includes endoscopes, cameras, microscopes, imaging software, and accessories. Brands in this field include Nikon Instruments, Zeiss, and Lumera. Genomics: Bio-Techne's genomics offering includes custom gene synthesis, antisense oligonucleotides, miRNA inhibitors, as well as PCR, qPCR, and sequencing kits and reagents. The company also provides comprehensive genomics services including analysis, sequencing, and data analysis. Clinical diagnostics: Bio-Techne provides solutions for clinical diagnostics, including IVD reagents, custom biomarker development and services, immunohistochemistry test systems, as well as devices and instruments for clinical sample submission. Brands in this field include R&D Systems, Novus Biologicals, and Exosome Diagnostics. Summary: Overall, Bio-Techne Corp offers a wide range of solutions for the biotechnology and clinical diagnostics industry. With its leading brands and extensive range of products and services, the company has established itself as a key player in this field. Through continuous product and service development and innovation, Bio-Techne is able to maintain its market share and further expand its business in various niche markets.
Il fatturato di Bio-Techne ammonta a 1,22 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il profitto di Bio-Techne ammonta a 181,86 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Bio-Techne è attualmente 62,51. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Bio-Techne.
Il rapporto prezzo/fatturato (P/S) di Bio-Techne è attualmente 9,36. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Bio-Techne.
Il Quality Score AlleAktien per Bio-Techne è 5/10.
L'ISIN di Bio-Techne è US09073M1045. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Bio-Techne è A12ENG. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Bio-Techne è TECH. Con questo simbolo di borsa vengono negoziate le azioni Bio-Techne in borsa.
Azione Bio-Techne
Gruppo di pari di Bio-Techne
Bio-Techne Ticker
Bio-Techne FIGI
Altre metriche e analisi di Bio-Techne in Deep Dive.
La nostra analisi azionaria dell'azione Bio-Techne include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Bio-Techne. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: